HDM2020
/ Huadong Medicine
- LARVOL DELTA
Home
Next
Prev
1 to 3
Of
3
Go to page
1
October 04, 2025
A phase I clinical study to evaluate the safety, tolerability, efficacy, and pharmacokinetics of HDM2020 (FGFR2b-ADC) in patients with advanced solid tumors
(ESMO Asia 2025)
- P1 | "All patients in this study will be required to provide tumor samples for FGFR2 IHC testing. Phase Ia will enroll patients with FGFR2 expression, defined by ≥1% tumor cells showing FGFR2 membrane protein expression intensity 1+, 2+, or 3+; In phase Ib, patients with positive FGFR2 expression will be enrolled, defined as ≥5% or 10% tumor cells showing FGFR2 membrane protein expression intensity 2+, or 3+."
Clinical • Metastases • P1 data • PK/PD data • Biliary Cancer • Cholangiocarcinoma • Gastric Cancer • Oncology • Ovarian Cancer • Solid Tumor • FGF10 • FGFR2 • TOP1
August 02, 2025
A Study of HDM2020 in Patients With Advanced Solid Tumors
(clinicaltrials.gov)
- P1 | N=60 | Recruiting | Sponsor: Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
New P1 trial • Solid Tumor
March 26, 2025
Preclinical development of HDM2020, a novel ADC targeting FGFR2b, in gastric cancer (GC) and squamous non-small cell lung cancer (sq-NSCLC) xenograft models
(AACR 2025)
- "FGFR2b expression were detected by IHC using various tumor paraffin sections. Combination of HDM2020 and avastin or paclitaxel demonstrated a synergistic effect in GC CDX model. Based on the clinical validation of FGFR2b in GC and signs of early preclinical activity in sq-NSCLC with significant unmet need, HDM2020 might has promising efficacy in these indications. HDM2020 is expected to enter clinical development in 2025.References:1: Seiya Sato, Shannon L Rhodes, et al. Fibroblast Growth Factor Receptor 2 Isoform IIIb (FGFR2b) Protein Overexpression and Biomarker Overlap in Patients With Advanced Gastric or Gastroesophageal Junction Cancer(GC/GEJC)."
IO biomarker • Preclinical • Esophageal Cancer • Gastric Cancer • Gastroesophageal Junction Adenocarcinoma • Lung Cancer • Lung Non-Small Cell Squamous Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer • BCOR • CLDN18 • FGFR2 • HER-2 • TP53
1 to 3
Of
3
Go to page
1